What is Phagos?
Phagos is at the forefront of developing novel therapeutic solutions by harnessing the evolutionary power of bacteriophages. Their technology enables the rapid creation of customized medicines designed to target and neutralize antibiotic-resistant bacteria, offering a much-needed alternative to conventional treatments. With the potential to deliver results in as little as two months, Phagos aims to significantly impact the mortality and economic burdens associated with bacterial infections. The company's focus on efficiency and effectiveness positions it as a key player in the fight against a growing global health threat.
How much funding has Phagos raised?
Phagos has raised a total of $29M across 1 funding round:
Series A
$29M
Series A (2025): $29M with participation from Demeter, CapHorn, Hoxton Ventures, and Capagro
Key Investors in Phagos
Demeter
Demeter is a project focused on enhancing enzyme production for improved biogas yields, suggesting an interest in bio-based innovations and sustainable solutions.
CapHorn
CapHorn VC is an early-stage venture capital firm specializing in healthtech and enterprisetech, indicating a focus on innovative solutions that optimize healthcare systems and support digital transformation.
Hoxton Ventures
Hoxton Ventures is an early-stage venture capital firm that invests in European technology startups with global scaling potential, particularly those disrupting existing industries or creating new market categories.
What's next for Phagos?
The recent major strategic investment signals Phagos's transition into a scaling phase, likely focusing on expanding its research and development capabilities, accelerating clinical trials, and broadening its market reach. This capital infusion will be instrumental in advancing their pipeline of phage-based therapies and solidifying their position as a leader in the antimicrobial resistance space. Future endeavors will likely involve strategic partnerships within the healthcare ecosystem to ensure widespread access to their innovative treatments.
See full Phagos company page
